Evidence mapPaperPMID 39858932Full record

ReviewMicroorganisms2025

Skin Microbiota: Mediator of Interactions Between Metabolic Disorders and Cutaneous Health and Disease.

Magdalini Kreouzi, Nikolaos Theodorakis, Maria Nikolaou, Georgios Feretzakis, Athanasios Anastasiou, Konstantinos Kalodanis, Aikaterini Sakagianni

Abstract readReview
In one paragraph

Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Cosmetic Interventions for Skin Microbiome Modulation: Current Strategies and Future Directions.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2026
    Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Activity ofFrontiers in pharmacology · 2026
    Article
  13. Lyophilized Cell-Free Supernatants ofLife (Basel, Switzerland) · 2025
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Magdalini KreouziDepartment of Internal Medicine, Amalia Fleming General Hospital, 14, 25th Martiou Str., 15127 Athens, Greece.
Nikolaos TheodorakisNT-CardioMetabolics, Clinic for Metabolism and Athletic Performance, 47 Tirteou Str., 17564 Palaio Faliro, Greece.ORCID 0000-0003-0420-7327
Maria NikolaouDepartment of Cardiology & Preventive Cardiology Outpatient Clinic, Amalia Fleming General Hospital, 14, 25th Martiou Str., 15127 Melissia, Greece.ORCID 0000-0003-2481-5936
Georgios FeretzakisSchool of Science and Technology, Hellenic Open University, 18 Aristotelous Str., 26335 Patras, Greece.ORCID 0000-0002-3597-1187
Athanasios AnastasiouBiomedical Engineering Laboratory, National Technical University of Athens, 15780 Athens, Greece.ORCID 0000-0001-6679-3590
Konstantinos KalodanisDepartment of Informatics & Telematics, Harokopio University of Athens, 17676 Kallithea, Greece.ORCID 0000-0003-2456-9261
Aikaterini SakagianniIntensive Care Unit, Sismanogleio General Hospital, 37 Sismanogleiou Str., 15126 Marousi, Greece.ORCID 0000-0002-3199-9158

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic disorders, including type 2 diabetes mellitus (T2DM), obesity, and metabolic syndrome, are systemic conditions that profoundly impact the skin microbiota, a dynamic community of bacteria, fungi, viruses, and mites essential for cutaneous health. Dysbiosis caused by metabolic dysfunction contributes to skin barrier disruption, immune dysregulation, and increased susceptibility to inflammatory skin diseases, including psoriasis, atopic dermatitis, and acne. For instance, hyperglycemia in T2DM leads to the formation of advanced glycation end products (AGEs), which bind to the receptor for AGEs (RAGE) on keratinocytes and immune cells, promoting oxidative stress and inflammation while facilitating Staphylococcus aureus colonization in atopic dermatitis. Similarly, obesity-induced dysregulation of sebaceous lipid composition increases saturated fatty acids, favoring pathogenic strains of

Indexed as

acneatopic dermatitisbiomarkersmetabolic disordersprecision dermatologypsoriasisskin microbiota

Identifiers

PMID39858932
PMCPMC11767725

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.